. Flow chart of literature search.
. Level of evidence algorithm *When a meta-analysis had no evidence of publication bias or ES but had high in-between study heterogeneity (I 2 > 50), we rechecked the results of its component studies to find out whether high heterogeneity was due to the differences in the direction of effects or due to the differences in the size of the associations. When the number of statistically significant component studies was the same or greater than the number of studies which were not significant or significant in the opposite direction, the comparison was classified as suggestive evidence, or convincing evidence if further criteria were met.
*When no statistically significant component study was observed in a meta-analysis, the comparison was at best classified as weak evidence, even in the absence of biases. 2.25-5 7,075 1,007 380-1,224 0(0%) 0(0%) 8(100%) 7(88%) 1(13%) 6(75%) 2(25%) 4(50%) 4(50%) 0(0%) 8(100%) 3(38%) 5(63%) 0(0%) 8(100%) 0(0%) 0(0%) 0(0%) 8(100%) Vaccin e DC 2 5 14 3 2.5-3 1,694 86 67-737 1(20%) 1(20%) 3(60%) 5(100%) 0(0%) 3(60%) 2(40%) 0(0%) 5(100%) 1(20%) 4(80%) 4(80%) 1(20%) 0(0%) 5(100%) 0(0%) 1(20%) 1(20%) 3(60%)
Others or not specified 7 14 46 2.5 2-4.25 18,324 1,071 848-1,756 1(7%) 5(36%) 8(57%) 9(64%) 5(36%) 5(36%) 9(64%) 9(64%) 5(36%) 2(14%) 12(86%) 11(79%) 3(21%) 1(7%) 13(93%) 0(0%) 2(14%) 4(29%) 8(57%) Uncategorized immunotherapy 7 22 126 5 3-9 48,499 2,342 1,066-2,736 2(9%) 7(32%) 13(59%) 13(59%) 9(41%) 15(68%) 7(32%) 17(77%) 5(23%) 5(23%) 17(77%) 10(45%) 12(55%) 3(14%) 19(86%) 0(0%) 4(18%) 5(23%) 13(59%) 
Analyses of RCTs
Abbreviations: N., number; IQR, interquartile range; NA, not available; mAB, monoclonal antibody; ACI, adoptive cell immunotherapy; DC/CIK, dendritic cells with cytokine-induced killer cells; CIK, cytokine-induced killer cells; IFN-α, interferon alpha; IL-2, interleukin-2; DC, dendritic cells; IT, immunotherapy; RCT, randomized controlled trials. * 4 results from one article showed weak evidence in favor of the control therapy. † Value is rounded to the nearest unit. 
No association

Abbreviations
No association
Abbreviations: RCT, randomized controlled trial; N., number; SE, standard effect; CI, confidence interval; M, model; F, fixed effect; R, random effect; NA, not available; C, concordance with largest study; Y, concordant with largest study; N, not concordant with largest study; OS, overall survival; PFS progression-free survival; RR, risk ratio; HR, hazard ratio; OR, odds ratio; DC, dendritic cell based vaccine; P, placebo; VAX, cancer vaccine; CTx, chemotherapy; obs, observation; P, placebo; AT, adjuvant therapy; CT, conventional therapy; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma. * Value reported in original article of the meta-analysis. † Number of individual studies of effect size with statistical significance in the reverse direction/not statistically significant/statistically significant. ‡ Concordance of fixed and random effects summary outcome with outcome of largest individual study. § Value obtained from re-analysis of original meta-analysis. Re-analysis was performed after excluding non-RCTs from original meta-analysis. All p-Values are two-sided. Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
14-15
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
Risk of bias across studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
15
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
2-3
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
DISCUSSION
Summary of evidence
24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
12-13
Limitations 25
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
13-14
Conclusions 
